natgillin/translations-raw huggingface dataset:
FPV/RTV 700 mg/100 mg 2 gange daglig (n = 434) 
FPV/RTV 700 mg/100 mg BID (n= 434)
Til voksne med let nedsat leverfunktion (Child-Pugh Score: 5-6) er den anbefalede dosis 700 mg fosamprenavir 2 gange daglig i kombination med 100 mg ritonavir en gang daglig. 
For adults with mild hepatic impairment (Child-Pugh score: 5-6) the recommended dose is 700 mg fosamprenavir twice daily with 100 mg ritonavir once daily.
Der skal udvises forsigtighed ved samtidig administration af Telzir/ritonavir og parenteral midazolam. 
Telzir/ritonavir should not be co-administered with orally administered midazolam (see section 4.3), whereas caution should be used with co-administration of Telzir/ritonavir and parenteral midazolam.
Forsigtighed tilrådes ved doser, der er større end de anbefalede (se pkt. 
Caution is advised if the recommended dose of fosamprenavir with ritonavir detailed below are exceeded (see section 4.4).
Børn og unge: Bivirkningsprofilen hos børn og unge er baseret på integrerede sikkerhedsdata fra to studier (APV29005 uge 24 data og APV20003 uge 168 data [endelige data]). 
Children and adolescents: The adverse reaction profile in children and adolescents is based on integrated safety data from two studies (APV29005 Week 24 data and APV20003 Week 168 data [final data]) in which 158 HIV-1 infected subjects 2 to 18 years of age received fosamprenavir with ritonavir with background nucleoside reverse transcriptase inhibitor therapy (see section 5.1 for information on dosing regimens applied for each age group).
Det skal du vide, før du begynder at tage Telzir Sådan skal du tage Telzir Bivirkninger 
What Telzir is and what it is used for What you need to know before you take Telzir How to take Telzir
Didanosin-enterokapsel 
Didanosine gastro-resistant capsule
Ethinylestradiol: Cmax 28 % Ethinylestradiol: AUC 37 % 
Ethinyl estradiol: Cmax Ethinyl estradiol: AUC
Hver filmovertrukken tablet indeholder 700 mg fosamprenavir som fosamprenavircalcium (svarende til ca. 600 mg amprenavir) 
Each film-coated tablet contains 700 mg fosamprenavir as fosamprenavir calcium (equivalent to approximately 600 mg of amprenavir)
Co. Durham DL12 8DT Storbritannien eller 
Harmire Road Barnard Castle Co. Durham DL12 8DT United Kingdom
Til voksne med moderat nedsat leverfunktion (Child-Pugh Score: 7-9) er den anbefalede dosis 450 mg fosamprenavir 2 gange daglig i kombination med 100 mg ritonavir en gang daglig. 
For adults with moderate hepatic impairment (Child-Pugh score: 7-9) the recommended dose is 450 mg fosamprenavir twice daily with 100 mg ritonavir once daily.
b) Patienter, der tidligere har været behandlet med PI'er Amprenavir 
b) PI-experienced patients
Intrinsisk kortisolniveau:  
Fluticasone propionate: ↑ Intrinsic cortisol levels: ↓
1.000 - 10.000 kopier/ml 
1000 - 10,000 copies/ml >10,000 - 100,000 copies/ml >100,000 copies/ml AAUCMB Observed Analysis
LÆGEMIDLER MOD INFEKTIONER 
Medicinal products - interactions
Hvis du har en svær leversygdom, er dosis 6 ml Telzir oral suspension (300 mg fosamprenavir) 2 gange daglig med 100 mg ritonavir kun én gang daglig. 
If you have severe liver disease the dose is 6 ml Telzir oral suspension (300 mg fosamprenavir) twice daily with 100 mg ritonavir only once daily.
Otte patienter mellem 12 og 18 år blev behandlet med tabletstandarddoseringen til behandling af voksne på 700 mg fosamprenavir 2 gange daglig (i kombination med 100 mg ritonavir 2 gange daglig). 
In a clinical study on pharmacokinetics of fosamprenavir in paediatric patients, eight subjects 12 to 18 years of age received the standard fosamprenavir adult tablet dose of 700 mg twice daily (with ritonavir 100 mg twice daily).
Voksne bør tage den orale suspension uden mad og på tom mave. 
In adults, the oral suspension should be taken without food and on an empty stomach.
Amprenavir: AUC  82 % 
Amprenavir: AUC ↓ 82% Contraindicated (see section
Flecainid:  forventet Propafenon:  forventet (RTV hæmmer CYP2D6) 
Propafenone: ↑ expected (CYP2D6 inhibition by RTV)
(RTV hæmmer i mindre grad CYP2D6) 
(Mild CYP2D6 inhibition by RTV)
Norethisteron: Cmax 38 % Norethisteron: AUC 34 % Norethisteron: Cmin  26 % (FPV/RTV inducerer CYP3A4) 
Norethisterone: Cmax ↓ 38% Norethisterone: AUC ↓ 34% Norethisterone: Cmin ↓ 26
Samtidig behandling med Telzir og lavdosis ritonavir i kombination med rifampicin er kontraindiceret (se pkt. 
Combination of rifampicin with Telzir with concomitant low-dose ritonavir is contraindicated (see section 4.5).
Hepatitis C-virus (HCV) direkte virkende antivirale stoffer: Når hepatitis C-virus direkte virkende antivirale stoffer, som metaboliseres af CYP3A4, eller som er induktorer/hæmmere af CYP3A4, 
Hepatitis C virus (HCV) Direct-Acting Antivirals: When hepatitis C virus direct-acting antiviral (DAA) drugs, which are metabolised by CYP3A4 or are inducers/inhibitors of CYP3A4, are coadministered with fosamprenavir/ritonavir, altered plasma concentrations of medications are expected due to inhibition or induction of CYP3A4 enzyme activity (see sections 4.3 and 4.5).
Hvis du har en mild leversygdom, er dosis 14 ml Telzir oral suspension (700 mg fosamprenavir) 2 gange daglig med 100 mg ritonavir kun én gang daglig. 
If you have mild liver disease, the dose is 14 ml Telzir oral suspension (700 mg fosamprenavir) twice daily with 100 mg ritonavir only once daily.
Navn og adresse på den fremstiller, der er ansvarlig for batchfrigivelse 
A MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturers responsible for batch release Film-coated tablets
Resultater fra studier med andre hiv-proteasehæmmere og paritaprevir/ritonavir/ombitasvir +/- dasabuvir antyder, at samtidig administration af fosamprenavir/ritonavir og paritaprevir/ritonavir/ombitasvir +/- dasabuvir sandsynligvis medfører øget plasmakoncentration af paritaprevir pga. CYP3A4enzymhæmning og højere ritonavir-dosis. 
ombitasvir +/- dasabuvir suggest that coadministration of fosamprenavir/ritonavir with paritaprevir/ritonavir/ ombitasvir+/-dasabuvir is likely to lead to increased plasma exposures of paritaprevir due to CYP3A4 enzyme inhibition and higher ritonavir dose.
Resistente over for FPV/RTV ≥ 4 mutationer fra score 
≥ 4 mutations from score
ANTIPSYKOTIKA 
ANTIARRHYTHMICS
En ml oral suspension indeholder 50 mg fosamprenavir som fosamprenavircalcium (svarende til ca. 43 mg amprenavir). 
Each ml of oral suspension contains 50 mg fosamprenavir as fosamprenavir calcium (equivalent to approximately 43 mg amprenavir).
Frarådes. 
Not recommended.
Voksne patienter tidligere behandlet med antiretrovirale lægemidler 
Antiretroviral Experienced Adult Patients
En ml oral suspension indeholder 50 mg fosamprenavir som fosamprenavircalcium (svarende til ca. 43 mg amprenavir) 
Each ml of oral suspension contains 50 mg fosamprenavir as fosamprenavir calcium (equivalent to approximately 43 mg of amprenavir)
(FPV/RTV inducerer CYP3A4) 
(CYP3A4 induction by FPV/RTV)
Oversigt over indlægssedlen Virkning og anvendelse 
ANNEX III LABELLING AND PACKAGE LEAFLET
Børn kan tage en voksendosis på én 700 mg Telzir tablet 2 gange daglig sammen med 100 mg ritonavir 2 gange daglig, hvis de kan sluge tabletterne hele. 
Children from 6 years of age and weighing at least 39 kg Children can take the adult tablet dose of one 700 mg Telzir tablet twice daily with ritonavir 100 mg twice daily if they can swallow the tablets whole.
Integrasehæmmere 
Potential for increased
Følgende mutationer blev påvist hos de patienter, der fik virologsik svigt i løbet af 96 uger: L10F/I, L24I, V32I, L33F, M36I, M46I/L, I47V, I50V, I54L/M/S, A71I/T/V, G73S, V82A, I84V og L90M. 
In the studies of PI-experienced adult patients, APV30003 and its extension, APV30005 (fosamprenavir 700 mg / ritonavir 100 mg twice daily: n=107), the following mutations emerged in patients experiencing virological failure through 96 weeks: L10F/I, L24I, V32I, L33F, M36I, M46I/L, I47V, I50V, I54L/M/S, A71I/T/V, G73S, V82A, I84V, and L90M.
Itraconazol:  forventet (FPV/RTV hæmmer CYP3A4) 
Itraconazole: ↑ expected (CYP3A4 inhibition by FPV/RTV)
Hos personerne med moderat nedsat leverfunktion (Child-Pugh score på 7-9) forventes en reduceret dosis af fosamprenavir på 450 mg 2 gange daglig i kombination med 100 mg ritonavir reduceret til én gang daglig at give samme plasma-Cmax and plasma-AUC(0-12) for amprenavir, som dem, der blev opnået hos personer med normal leverfunktion og som fik administreret 700 mg fosamprenavir 2 gange daglig i kombination med 100 mg ritonavir 2 gange daglig. 
In subjects with moderate hepatic impairment (Child-Pugh score of 7-9), a reduced dose of fosamprenavir 450 mg twice daily with a reduced dosing frequency of ritonavir 100 mg once daily is predicted to deliver similar plasma amprenavir Cmax and AUC(0-12), but approximately 35 % lower plasma total amprenavir C12 values and approximately 88 % higher plasma unbound amprenavir C12 values than achieved in subjects with normal hepatic function receiving the standard fosamprenavir with ritonavir 700 mg / 100 mg twice daily regimen.
For kraftig sprøjten bagtil i halsen kan øge risikoen for, at du får væsken galt i halsen. 
Don't push too hard and squirt the liquid into the back of the throat or you may choke.
De nævnte mutationer sås kun sjældent, når ART-naive voksne patienter blev behandlet med de på nuværende tidspunkt godkendte doser af fosamprenavir/ritonavir. 
The mutational profiles were similar to those described for PIexperienced adults treated with fosamprenavir / ritonavir.
Hos personerne med let nedsat leverfunktion sås en let forhøjet plasma-Cmax for amprenavir (17 %), en let forhøjet plasma-AUC(0-12) for amprenavir (22 %), tilsvarende totale plasma-C12-værdier for amprenavir og cirka 117 % højere plasma-C12-værdier for ubundet amprenavir. 
In subjects with mild hepatic impairment (Child-Pugh score of 5-6), the dosage regimen of fosamprenavir 700 mg twice daily with a reduced dosing frequency of ritonavir 100 mg once daily provided slightly higher plasma amprenavir Cmax (17 %), slightly higher plasma amprenavir AUC(0-12) (22 %), similar plasma total amprenavir C12 values and approximately 117 % higher plasma unbound amprenavir C12 values compared to subjects with normal hepatic function receiving the standard fosamprenavir / ritonavir 700 mg /100 mg twice daily regimen.
• træthed 
• Feeling tired
Forhøjet kolesterol i blodet 
Blood cholesterol increased Blood triglycerides increased Alanine aminotransferase increased
Blødere kan bløde mere 
Haemophiliacs may bleed more
For fosamprenavir var Cmax-værdien ca. 30 % lavere og Cmin-værdien ca. 28 % højere. 
After multiple dose oral administration of equivalent fosamprenavir and amprenavir doses, comparable amprenavir AUC values were observed; however, Cmax values were approximately 30 % lower and Cmin values were approximately 28 % higher with fosamprenavir.
PDE5-hæmmere:  forventet (FPV/RTV hæmmer CYP3A4) 
PDE5 inhibitors: ↑ expected (CYP3A4 inhibition by FPV/RTV)
Lidocain:  forventet (FPV/RTV hæmmer CYP3A4) 
Lidocaine: ↑ expected (CYP3A4 inhibition by FPV/RTV)
(FPV/RTV hæmmer CYP3A4) 
(CYP3A4 inhibition by FPV/RTV)
Tabel over bivirkninger 
Uncommon side effects
NEUROLEPTIKA 
NEUROLEPTIC Pimozide
Kvalme eller opkastning, mavesmerter, løs afføring 
• Feeling sick or being sick (nausea or vomiting), pain in the stomach, loose stools
Pimozid:  forventet (FPV/RTV hæmmer CYP3A4) 
Pimozide: ↑ expected (CYP3A4 inhibition by FPV/RTV)
Erythromycin:  forventet (FPV/RTV hæmmer CYP3A4) 
Erythromycin: ↑ expected (CYP3A4 inhibition by FPV/RTV)
Leversygdomme 
Liver disease
Halofantrin:  forventet (FPV/RTV hæmmer CYP3A4) 
Halofantrine: ↑ expected (CYP3A4 inhibition by FPV/RTV)
Muskelproblemer 
You may experience muscle problems
• hvis du lider af hæmofili (blødersygdom). 
• If you have haemophilia.
Der er dog ingen kliniske studier eller postmarketingsdata, der tyder på, at disse hepatocellulære fund har klinisk betydning. 
The relevance of the hepatocellular findings in the rodents for humans is uncertain; however, there is no evidence from clinical trials or marketed use to suggest that these findings are of clinical significance.
Halofantrin 
Abacavir
Cisaprid:  forventet (FPV/RTV hæmmer CYP3A4) 
Cisapride: ↑ expected (CYP3A4 inhibition by FPV/RTV)
Børn i aldersgruppen 6 til 11 år (n=9) blev behandlet med 18 mg fosamprenavir/kg og 3 mg ritonavir/kg 2 gange daglig. 
Children 6 to 11 years of age (n=9) receiving fosamprenavir / ritonavir 18 / 3 mg/kg twice daily had 26 % higher AUC(0-24) and similar Cmax and Cmin values when compared to the historical adult population receiving fosamprenavir / ritonavir 700 / 100 mg twice daily.
Den er forbundet med øget fænotyperesistens over for fosamprenavir i kombination med ritonavir samt som reduceret sandsynlighed for virologisk respons (resistens). 
I62V, V82A/C/F/G, I84V and L90M and is associated with increased phenotypic resistance to fosamprenavir with ritonavir as well as reduced likelihood of virological response (resistance).
Bivirkninger 
ERGOT DERIVATIVES
Telzir i kombination med en lav dosis ritonavir er ikke tilstrækkeligt undersøgt hos patienter, der har fået antiretroviral behandling i en længere periode. 
In heavily pretreated patients the use of Telzir in combination with low dose ritonavir has not been sufficiently studied.
Propylparahydroxybenzoat (E216) 
methyl parahydroxybenzoate (E218), propyl parahydroxybenzoate (E216).
Didanosin-tyggetablet 
ANTICONVULSANTS Phenytoin
Hver filmovertrukken tablet indeholder 700 mg fosamprenavir som fosamprenavircalcium (svarende til ca. 600 mg amprenavir). 
QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 700 mg of fosamprenavir as fosamprenavir calcium (equivalent to approximately 600 mg of amprenavir).
Phenytoin 300 mg én gang daglig 
Atazanavir 300 mg once daily
Astemizol:  forventet Terfenadin:  forventet (FPV/RTV hæmmer CYP3A4) 
Lovastatin: ↑ expected Simvastatin: ↑ expected (CYP3A4 inhibition by FPV/RTV)
Følsomme over for FPV/RTV < 4 mutationer fra score 
Resistant to FPV/RTV
Hold øje med følgende: 
Signs to look out for include:
FPV/RTV 700 mg/100 mg 2 gange daglig (n=105) 
FPV/RTV 700 mg/100 mg
(FPV/RTV inducerer CYP3A4 beskedent) 
(Modest induction of CYP3A4 by FPV/RTV)
90 x 1 tablet (enkeltdosisblister) 
90 x 1 tablets (unit dose)
Pulver: 32,27 g 1 flaske 
32.27 g
Pulver til oral suspension 
Powder for oral suspension bottle (glass)
Intravenøs anvendelse Hætteglas (glas) 20 ml 
Solution for injection Intravenous use vial (glass)
Flaske (glas) 
1 bottle
Pakningsstørrelse t r 
l t o r
Lægemiddelform Indgivelsesvej Emballage 
Pharmaceutical Form Route of administration
Dette sammendrag blev sidst ajourført i 2-2013. 
This summary was last updated in 2-2013.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Adasuve den 20. februar 2013 
The European Commission granted a marketing authorisation valid throughout the European Union for Adasuve on 20 February 2013.
Dette er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Adasuve. 
This is a summary of the European public assessment report (EPAR) for Adasuve.
Den fuldstændige EPAR for Adasuve findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
The full EPAR for Adasuve can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Dets virkning på receptorerne for andre neurotransmitter kan også spille en rolle. 
Its action on receptors for other neurotransmitters may also play a role.
Hvad sikkerheden angår, er de fleste bivirkninger sammenlignelige med bivirkningerne af andre antipsykotiske lægemidler. 
Regarding its safety, most side effects are comparable to those of other antipsychotic medicines.
Uro er en kendt komplikation ved begge sygdomme. 
Agitation is a known complication of both mental illnesses.
Andre oplysninger om Adasuve 
Other information about Adasuve
Patienterne bør observeres for tegn på kortåndethed en time efter hver dosis. 
Patients should be observed for signs of shortness of breath for one hour after each dose.
Virkningerne af Adasuve blev først afprøvet i forsøgsmodeller, inden de blev undersøgt hos mennesker. 
The effects of Adasuve were first tested in experimental models before being studied in humans.
Adasuve var mere effektivt end placebo til at kontrollere uro. 
Adasuve was more effective than placebo at controlling agitation.
Adasuve loxapin 
Adasuve loxapine
Ved undersøgelsens begyndelse var PEC-score mellem 17 og 18 i disse patientgrupper. 
The PEC score at the beginning of the study for these groups of patients was between 17 and 18.
Adasuve er blevet anvendt i to hovedundersøgelser. 
Adasuve has been studied in two main studies.
CHMP konkluderede, at fordelene ved Adasuve overstiger risiciene, og anbefalede udstedelse af markedsføringstilladelse. 
The CHMP concluded that the benefits of Adasuve outweigh its risks and recommended that it be granted marketing authorisation.
Den virksomhed, der fremstiller Adasuve, sørger for, at alle sundhedspersoner, der forventes at anvende Adasuve, modtager en informationspakke med de vigtigste oplysninger om, hvordan lægemidlet skal bruges, samt vigtig sikkerhedsinformation. 
The company that makes Adasuve must ensure that all healthcare professionals who are expected to use Adasuve receive an information pack containing key information on how to use the medicine as well as important safety information.
Et fald i PEC-score betyder en bedring af symptomerne. 
A fall in PEC score indicates an improvement in symptoms.
Det forklarer, hvordan Udvalget for Lægemidler til Mennesker (CHMP) vurderede lægemidlet og nåede frem til sin udtalelse til fordel for udstedelse af en markedsføringstilladelse og til sine anbefalinger om anvendelsesbetingelserne for Adasuve. 
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Adasuve.
Hvis du ønsker yderligere oplysninger om behandling med Adasuve, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek. 
For more information about treatment with Adasuve, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Oplysninger om brugen af inhalatoren findes i indlægssedlen. 
Information on how to use the inhaler can be found in the package leaflet.
Den ene omfattede 344 patienter med skizofreni, den anden 314 patienter med bipolær sygdom. 
One study involved 344 patients with schizophrenia and the second study involved 314 patients with bipolar disorder.
Da disse neurotransmittere er medvirkende ved uro ved skizofreni og ved bipolar sygdom, normaliserer loxapin hjerneaktiviteten og mindsker uroen. 
Since these neurotransmitters are involved in agitation in schizophrenia and bipolar disorder, loxapine helps to normalise the activity of the brain, reducing agitation.
Risikoen for bronkiekramper anses for at være håndterbar og er blevet imødegået tilfredsstillende med risikonedsættende foranstaltninger. 
The potential risk of bronchospasm is considered manageable and has been adequately addressed through risk minimisation measures.
Hvilke foranstaltninger træffes der for at sikre risikofri anvendelse af Adasuve? 
What measures are being taken to ensure the safe use of Adasuve?
Derved afbrydes de signaler, som hjernecellerne sender til hinanden ved hjælp af “neurotransmittere”, dvs. kemiske stoffer, som nervecellerne kommunikerer med indbyrdes. 
This disrupts signals transmitted between brain cells by ‘neurotransmitters', chemicals that allow nerve cells to communicate with each other.
Adasuve er et lægemiddel, der indeholder det aktive stof loxapin. 
Adasuve is a medicine that contains the active substance loxapine.
Det leveres som et inhalationspulver i en bærbar inhalator til engangsbrug (4,5 mg og 9,1 mg). 
It is available as an inhalation powder in a portable inhaler device for single use (4.5 mg and 9.1 mg).
Adasuve må ikke anvendes hos personer, der er overfølsomme (allergiske) over for loxapin eller andre af indholdsstofferne. 
Adasuve must not be used in people who are hypersensitive (allergic) to loxapine or any of the other ingredients.
Loxapin menes hovedsagelig at virke på receptorerne for neurotransmitterne 5-hydroxytryptamin (serotonin) og dopamin. 
Loxapine works mainly by blocking receptors for the neurotransmitters 5-hydroxytryptamine (also called serotonin) and dopamine.
Det aktive stof i Adasuve, loxapin, er et antipsykotisk lægemiddel. 
The active substance in Adasuve, loxapine, is an antipsychotic medicine.
Det må heller ikke anvendes hos patienter med symptomer som hvæsende vejrtrækning eller stakåndethed eller med lungesygdomme som astma eller kronisk obstruktiv lungesygdom (KOL). 
It must also not be used in patients with symptoms such as wheezing and shortness of breath or who have lung conditions such as asthma or chronic obstructive pulmonary disease.
I begge undersøgelser blev 4,5 mg og 9,1 mg Adasuve sammenlignet med placebo (virkningsløs behandling). 
Both studies compared 4.5 mg and 9.1 mg of Adasuve with placebo (a dummy treatment).
Adasuve må kun administreres i hospitalsomgivelser under opsyn af sundhedspersoner. 
Adasuve should only be used in a hospital under the supervision of a healthcare professional.
Hvilken risiko er der forbundet med Adasuve? 
What is the risk associated with Adasuve?
Skizofreni er en psykisk sygdom, der giver symptomer bl.a. i form af ankeforstyrrelser og taleforstyrrelser, hallucinationer (opfattelsen af at høre eller se ting, som ikke er der), mistænksomhed og vrangforestillinger. 
Schizophrenia is a mental illness that has a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs).
Hvorfor blev Adasuve godkendt? 
Why has Adasuve been approved?
I stedet for en begyndelsesdosis på 9,1 mg kan der gives en lavere dosis på 4,5 mg, hvis den højere dosis ikke tåles af patienten, eller hvis lægen anser en lavere dosis for mere hensigtsmæssig. 
A lower dose of 4.5 mg may be prescribed if the patient did not tolerate the initial dose of 9.1 mg or if a lower dose is considered more appropriate.
Adasuve anvendes til hurtig kontrol af let til moderat uro hos voksne med skizofreni eller bipolær sygdom. 
Adasuve is used to rapidly control mild to moderate agitation in adults with schizophrenia or bipolar disorder.
I hjernen bindes det til forskellige typer receptorer på nervecellernes overflade og blokerer derved disse receptorer. 
In the brain, it attaches to and blocks several different receptors on the surface of nerve cells.
CHMP konkluderede, at det er påvist, at Adasuve giver hurtig kontrol (i løbet af minutter) af let til moderat uro ved skizofreni eller bipolær sygdom, når patienten er samarbejdsvillig ved brug af inhalator. 
The CHMP concluded that Adasuve has been demonstrated to rapidly control (within minutes) mild to moderate agitation in patients with schizophrenia or bipolar disorder who are cooperative with using an inhaler.
Til sammenligning var der et fald på 4,7 point hos dem, der fik placebo. 
This compared with a fall of 4.7 points in patients taking placebo.
Den fuldstændige liste over indberettede bivirkninger med Adasuve fremgår af indlægssedlen. 
For the full list of all side effects reported with Adasuve, see the package leaflet.
De almindeligste bivirkninger med Adasuve er smagsforstyrrelser, sløvhed eller søvnighed samt svimmelhed. 
The most common side effects with Adasuve are dysgeusia (taste disturbances), sedation or somnolence (sleepiness) and dizziness.
Til sammenligning var der et fald på 5,8 point hos dem, der fik placebo. 
This compared with a fall of 5.8 points in patients taking placebo.
I undersøgelsen med skizofreni var der et gennemsnitligt fald på 8,0 point i PEC-score hos patienter, der fik 4,5 mg Adasuve, og 8,7 point hos dem, der fik 9,1 mg Adasuve. 
In the study in patients with schizophrenia, patients taking 4.5 mg of Adasuve had an average fall in PEC score of 8.0 points and patients taking 9.1 mg had an average fall of 8.7 points.